Gene Therapy News 27 August 2025

Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Sources: Official press releases and filings investors.adverum.com investors.adverum.com, Reuters, Investing.com, Fierce Biotech fiercebiotech.com, and analyst reports marketbeat.com marketbeat.com. All data as of market close Oct. 23, 2025 and news through Oct. 24,

24 October 2025

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta’s Oct. 24 announcement ignited optimism. According to the official press release, Anemocyte will incorporate Genenta’s clinically validated LVV plasmid DNA platform (originating from Naldini’s research) into its production pipeline investing.com. “By

24 October 2025

Biotechnology · Gene Therapy · Investment Analysis · NASDAQ:GNTA · Pharma News · Stock Market

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Stock Price & Recent Performance Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours

15 October 2025

Biotechnology · Gene Therapy · Health News · Lung Cancer · NASDAQ:GNPX · Stock Market

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

Stock Performance: Wild Swings from Deaths to Resumption SRPT has been a roller-coaster. In early 2025, Sarepta’s shares were largely pummeled by the DMD gene-therapy crisis. After two Duchenne patients (non-ambulatory teens)

3 October 2025

Biotechnology · FDA News · Gene Therapy · Healthcare Investing · NASDAQ:SRPT · Stock Market · Stocks

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Stock Performance and Trends Sarepta’s stock is recovering some ground after steep losses. As of Oct 2, 2025, SRPT closed at $19.57, up about 6.8%for the day investing.com. This followed a general uptrend in recent

2 October 2025

Biotech · FDA Approvals · Gene Therapy · NASDAQ:SRPT · Pharmaceuticals · Stock Analysis · Stock Market

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For?

Key facts (quick read) In‑depth report 1) Huntington’s disease, in plain English What it is. HD is a progressive brain disorder that typically begins in mid‑adulthood, causing a mix of movement (chorea, dystonia),

26 September 2025

Gene Therapy · Huntington’s Disease · Medical Breakthroughs · NASDAQ:QURE · NASDAQ:WVE · Neuroscience · NYSE:NVS · Patient Stories

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

Stock Performance and Valuation Metrics uniQure’s stock performance in 2025 has been remarkably strong, capped by the explosive move on Sep. 24 after the Huntington’s data release. Prior to the announcement, QURE was

24 September 2025

Biotechnology · Gene Therapy · Huntington’s Disease · Medical Breakthroughs · NASDAQ:QURE · Stock Market

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Key Facts Sources

27 August 2025

Biotech · Gene Therapy · Health · NASDAQ:PGEN · NYSE:ABBV · NYSE:LLY · Obesity · Psychedelics

Gene Therapy News 27 August 2025 - 24 October 2025